These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20675691)

  • 1. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
    Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
    Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
    Fontana RJ; Bonkovsky HL; Naishadham D; Dienstag JL; Sterling RK; Lok AS; Su GL;
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):219-26. PubMed ID: 19068241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
    Fontana RJ; Litman HJ; Dienstag JL; Bonkovsky HL; Su G; Sterling RK; Lok AS;
    Liver Int; 2012 Apr; 32(4):665-74. PubMed ID: 22103814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
    Fontana RJ; Goodman ZD; Dienstag JL; Bonkovsky HL; Naishadham D; Sterling RK; Su GL; Ghosh M; Wright EC;
    Hepatology; 2008 Mar; 47(3):789-98. PubMed ID: 18175357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
    Hoefs JC; Shiffman ML; Goodman ZD; Kleiner DE; Dienstag JL; Stoddard AM;
    Gastroenterology; 2011 Sep; 141(3):900-908.e1-2. PubMed ID: 21699796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
    Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
    Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
    Dienstag JL; Ghany MG; Morgan TR; Di Bisceglie AM; Bonkovsky HL; Kim HY; Seeff LB; Szabo G; Wright EC; Sterling RK; Everson GT; Lindsay KL; Lee WM; Lok AS; Morishima C; Stoddard AM; Everhart JE;
    Hepatology; 2011 Aug; 54(2):396-405. PubMed ID: 21520194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
    Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
    Dultz G; Seelhof M; Herrmann E; Welker MW; Friedrich-Rust M; Teuber G; Kronenberger B; von Wagner M; Vermehren J; Sarrazin C; Zeuzem S; Hofmann WP
    PLoS One; 2013; 8(8):e71262. PubMed ID: 23936497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).
    Curto TM; Lagier RJ; Lok AS; Everhart JE; Rowland CM; Sninsky JJ;
    Pharmacogenet Genomics; 2011 Dec; 21(12):851-60. PubMed ID: 21946897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.